A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3)
Administered By
Awarded By
Contributors
- Choi, Taewoong Principal Investigator
Start/End
- September 30, 2019 - October 14, 2024